november 4, 2013 co g nitiv e faster learning healt ... synapsa customer presentation 1… ·...
TRANSCRIPT
![Page 1: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/1.jpg)
CO
GNOVEMBER 4, 2013 GN
ITIVE
FASTER LEARNING
ENHANCED MEMORY
E H
EA
LT
ENHANCED MEMORY
IMPROVED MENTAL PERFORMANCE
H
A FOUNDATIONAL INGREDIENT FOR COGNITIVE HEALTH
PERFORMANCE
A FOUNDATIONAL INGREDIENT FOR COGNITIVE HEALTH FORMULATIONS SUPPORTING MEMORY, LEARNING AND INTELLECTUAL PERFORMANCE
1
![Page 2: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/2.jpg)
TODAY’S MEETING
Welcome to the brave new world of Synapsa™!
MARKET OPPORTUNITY • Cognitive Healthg• The information age demographic
ABOUT SYNAPSA™• A unique, proprietary ingredientA unique, proprietary ingredient
DEEP DIVE ON THE RESEARCH• 30 years of study• Highlights of 4 clinical studies
WE’RE PLEASED TO HAVE THE Highlights of 4 clinical studies
CLAIMS, IP & MORE
DISCUSSION
OPPORTUNITY TO MEET WITH YOU TODAY!
DISCUSSION
2
![Page 3: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/3.jpg)
THE COGNITIVE HEALTH SEGMENTH ge opport nit for gro th
MA
R
CONSUMER CONCERN OVER MENTAL ABILITY GREW 47% OVER THE PAST DECADE – HEALTH Attention
M
Huge opportunity for growth
RK
ET O
P
FOCUS INTERNATIONAL• Broad range of the population is concerned about
mental functioning• 33% over 65
MemoryLanguage LearningReasoning
PP
OR
TU
• 26% 18-29
“COGNITIVE HEALTH SUPPLEMENT SALES ARE POISED TO SKYROCKET” – NBJ
gProblem solvingMoodSleep
UN
ITY
• 2011 U.S. cognitive health sales grew 6% to $1.4B• Ground floor opportunity: The category accounts for less
than 5% of U.S supplement sales
HUGE MARKET OPPORTUNITY WITHHIGH GROWTH PROSPECTS
3
![Page 4: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/4.jpg)
PEAK PERFORMANCEA i ti d i t it
MA
R
MOST COGNITIVE HEALTH SUPPORT STUDIES & SUPPLEMENTS FOCUS ON
PEAK PERFORMERS IN THE USA
An existing and growing opportunity
RK
ET O
PSTUDIES & SUPPLEMENTS FOCUS ON ISSUES OF COGNITIVE DECLINE
VAST NEED & MARKET OPPORTUNITY
IN THE USA
Knowledge workersOver 100 million in 2014(Infotrends 2011)
PP
OR
TU
VAST NEED & MARKET OPPORTUNITY FOR SUPPORT IN AREAS OF COGNITIVE PERFORMANCE RELATED TO STUDY & WORK
(Infotrends, 2011)
College & University Students21.8 million in 2013 (US Dept of Education)
UN
ITY
40% of
WORK (US Dept. of Education)
40% of US population
4
![Page 5: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/5.jpg)
ALREADY AN ACTIVE MARKETC ff i & th “ ti l t ”
MA
R
STUDENTS
Caffeine & other “stimulants”
RK
ET O
P
UndergraduatePost GraduateMedicalLegal
PP
OR
TULegal
KNOWLEDGE WORKERS
UN
ITY
WORKERSSoftwareArchitectsEngineers
Nearly 63% of medical students report ‘academic performance’ as
ScientistsFinancial servicesLegalMedia/Social Media
reason for consuming caffeine (Lee K-H, et al 2009)
Media/Social Media
5
![Page 6: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/6.jpg)
A PLATFORM FOR ‘PEAK PERFORMANCE’S ™ N t l M S t
MA
R
Safe, natural support Quality
Synapsa™ Natural Memory Support
RK
ET O
P, ppfor healthy adults looking for ‘peak performance’
Q yControl
Cli i lO
PP
OR
TU
• Learning• Memory• Academic
Clinical Support
Ongoing Research
UN
ITY
performance• Workplace
performanceIP
New Product IPProduct
Concepts
6
![Page 7: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/7.jpg)
ING
RRE
DIE
N
THE FUTURE OF QUALITY
NT Q
UA
L
OF QUALITY
LITY
PATENTED EXTRACTSEED-TO-SHELF QUALITY
7
![Page 8: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/8.jpg)
A UNIQUE COMPOSITIONCli i ll t di d i di t d d b t t d
ING
R
MULTI-PATENTED PROCESS
Clinically studied ingredient produced by patented process
RE
DIE
N
The unique method• India 185078 (2961/DEL/1996): extraction
of a formulations mainly containing bacosides
NT Q
UA
L
,
The unique method of making Synapsa™ – the clinically-studied ingredient – LITY
gis patented.
8
![Page 9: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/9.jpg)
SEED-TO-SHELF QUALITYKe to reprod cible clinical trial res lts
ING
R
Each step can influence th fi l d t’
Synapsa™ is a unique extract of Bacopa monnieri, with a wide range of Seed
Key to reproducible clinical trial results
RE
DIE
N
the final product’s complex phytochemical profile and therapeutic action
p , gactive constituents that contribute to its therapeutic properties
Result of over 30 years extensive
Planting
Growing
NT Q
UA
L
Putting farming & manufacturing controls in place across each step allows for consistency of the
yresearch & development at the Central Drug Research Institute (CDRI) in India
Consistent farming & manufacturing
Harvesting
Extraction
LITY
consistency of the entire product & results in a product that can be clinically studied
g gprocesses from to ensure a standardized level of quality Production
Storage
9
![Page 10: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/10.jpg)
CLINN
ICA
L R
THE FUTURE OF COGNITIVE
RE
SE
AR
CCOGNITIVE RESEARCH
CH
A FOCUS ON HEALTHY ADULTS
10
![Page 11: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/11.jpg)
COGNITIVE BENEFIT AREASD t f li i l t i l h t ti ti ll i ifi t lt
VALU
FASTER INFORMATION PROCESSING These studies focus
Data from clinical trials show statistically significant results UE
PR
O
IMPROVED LEARNING RATE
DECREASED FORGETTING RATE
,These studies focus on healthy adults from 18 to 65
OP
OS
ITI
IMPROVED MEMORY CONSOLIDATION
BETTER MULTI-TASKING ACCURACY
ON
SYNAPSA™ STUDIES SHOW BOTH CHRONIC AND ACUTE EFFICACY
11
![Page 12: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/12.jpg)
COGNITIVE STUDY BACKGROUNDSt li i l t
CLIN
• 7 ‘foundational’ clinical trials The scientific
Strong clinical support
NIC
AL R
• 6 ‘targeted’ randomized, double-blind, placebo-controlled clinical trials
• Additional clinical trials underway and ,
evidence for the cognitive enhancing effect of S ™ N t l
RE
SE
AR
C
planned
• Synapsa™ has been shown to be safe, well tolerated and devoid of
,Synapsa™ Natural Memory Support is based on 30 years of research
CH
undesirable side effects in clinical studies
years of research
12
![Page 13: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/13.jpg)
SUMMARY OF CLINICAL PROGRAMCh i d t ff t f S ™
CLIN
Chronic Use of Synapsa™ – Key StudiesStough et al. The chronic effects of an extract of Bacopa monnieri on cognitive function in healthy human subjects Psychopharmacology 2001; 156:481 484
Chronic and acute effects of Synapsa™
NIC
AL R
human subjects, Psychopharmacology, 2001; 156:481-484.Roodenrys et al. Chronic effects of Brahami on human memory, Neuropsychopharmacology, 2002; 27:279-281.Raghav et al. Randomized controlled trial of standardized Bacopa monnieri extract in age-associated memory impairment Indian Journal of Psychiatry 2006; 48:238 242
RE
SE
AR
Cmemory impairment, Indian Journal of Psychiatry, 2006; 48:238-242. Stough et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning, Phytotherapy Research, 2008; 22:1629-1634.
Acute Use of Synapsa™ – Key Studies
CH
Nathan et al. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects, Human Psychopharmacology, 2001; 16:345-351.Downey et al. An Acute, Double-Blind, Placebo-Controlled Crossover Study of 320 mg and 640 mg Doses of a Special Extract of Bacopa monnieri (CDRI 08) on Sustained Cognitive Performance. p p ( ) gPhytotherapy Research 2012; 27:1407-1413.Benson S, Downey LA, Stough C et al. An Acute, Double-Blind, Placebo-Controlled Cross-over Study of 320 mg and 640 mg Doses of Bacopa monnieri (CDRI 08) on Multitasking Stress Reactivity and Mood. Phytotherapy Research 21 Jun 2013y py
13
![Page 14: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/14.jpg)
STOUGH, ET AL. 2001Vi l i l i t & lid ti
CLIN
Details Summary of Results• Double-blind placebo-controlled, Significant improvement in:
Visual processing, learning rate & memory consolidation
NIC
AL R
Double blind placebo controlled, • 46 healthy participants, 18-60 yrs • 3 months, 300 mg/d Synapsa™• Independent-group design
Significant improvement in:• Information processing• Memory consolidation• Reduction in state anxiety
RE
SE
AR
C
• t = baseline, 5 & 12 weeksMaximal effects evident after 12 weeks
CH
14
![Page 15: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/15.jpg)
ROODENRYS, ET AL. 2002I f ti t ti
CLIN
Details Summary of Results• Double-blind placebo-controlled, Significant effect on:
Information retention
NIC
AL R
• 76 healthy participants, 40-65 yrs• 3 months, 300 mg/d Synapsa™,
followed by 6 week post-trial assessment
• Retention of new information, • Verbal and visual short-term
memory.
RE
SE
AR
Cassessment• t = baseline, 90 days & 6 weeks post
treatment
CH
15
![Page 16: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/16.jpg)
STOUGH, ET AL. 2008W ki i l i f ti i &
CLIN
Details Summary of Results
Working memory, visual information processing & accuracy
NIC
AL R
y• Double-blind, placebo-controlled• 107 healthy participants, 18-60
3 months, 300 mg/d Synapsa™t b li d 90 d
Significant improvements in:• Working Memory • Visual Information Processing
RE
SE
AR
C
• t = baseline and 90 days
CH
16
![Page 17: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/17.jpg)
DOWNEY, ET AL. 2012I d f iti l d di t t ( t )
CLIN
Details Summary of Results
Improved performance on cognitively demanding tests (acute)
NIC
AL R
• Double-blind, placebo-controlled, cross-over
• 24 healthy adults subjects• 320mg 640mg acute doses Synapsa™
Improved performance on cognitively demanding tests from 320 mg dose (Cognitive Demand Battery)
RE
SE
AR
C• 320mg, 640mg acute doses Synapsa™ Battery)
THE CDR SYSTEM:
CH
• Used in worldwide clinical trials since 1984. Over 900 trials.
• Attention, Concentration, Vigilance
• Working (Short Term) Memory• Working (Short-Term) Memory
• Episodic (Long-Term) Memory
17
![Page 18: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/18.jpg)
ON-GOING STUDIES CLIN
One of the most
NIC
AL R
Additional indications/targets:
aggressive & comprehensive research programs
f iti h lth
RE
SE
AR
C
• Inattention• Acute dosing• Cognition enhancement• fMRI
of a cognitive health ingredient in the industry
CH
• fMRI • Dementia/Alzheimer’s• Basic pharmacology
18
![Page 19: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/19.jpg)
MA
RRK
ET O
P
THE FUTURE OF EXCITING NEW
PP
OR
TUEXCITING NEW PRODUCTS
UN
ITY
NEW INDICATIONSNEW IPNEW CLAIMS
19
![Page 20: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/20.jpg)
ADDRESSING THE AGING POPULATIONS ™ A t li R h C il’ Ch i f B
CLIN
ARCLI (AUSTRALIAN RESEARCH Aging population h ld t
Synapsa™: Australian Research Council’s Choice of Bacopa
NIC
AL R
COUNCIL LONGEVITY INTERVENTION)• 465 cognitively healthy older adults (60-75
years old) are being randomized to receive Synapsa™ (300 mg) Pycnogenol (150 mg)
should want Synapsa™ now… and even more in the future
RE
SE
AR
CSynapsa (300 mg), Pycnogenol (150 mg), or placebo daily for 12 months
• Participants will be evaluated at baseline, 3, 6 and 12 months post-randomization for a
the future CH
variety of cognitive, cardiovascular, and biochemical parameters
• Design published in the Nutrition Journal, 20122012
20
![Page 21: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/21.jpg)
PATENT PENDING FILINGA t t S ™ f t
MA
R
APPLICATION PATENT Patented support for t t t ki & th
A new patent on Synapsa™ for acute use
RK
ET O
P
• Pending: Methods for acutely improving/enhancing cognitive performance in a human subject
i i d i i t ti f t t
test taking & other peak performance cognitive environments
PP
OR
TU
comprising administration of an extract of Bacopa monnieri.
• Filing December 2013
environments
UN
ITY
21
![Page 22: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/22.jpg)
POTENTIAL PRODUCT CLAIMSCli i l t f diff t k t ff i
MA
R
• Clinically shown to improve the speed of information processing The scientific
Clinical support for different market offerings
RK
ET O
Pp g
• Supports the transition of short term memory to long term memory
• Aids in the retention of new information
The scientific evidence for the cognitive enhancing effect
PP
OR
TU
• Helps improve learning rate & memory
• A single ingredient that can support learning, memory, and mental performance
enhancing effect of Synapsa™ is based on 30 years of research
UN
ITY
• One ingredient. Better, faster learning.
• Better performance on cognitively demanding tests
years of research
• Improved mental performance when it counts
*The above claims are intended as suggestions only. Use of claims on product labeling and marketing materials should be vetted and approved by your regulatory and legal departments.
22
![Page 23: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/23.jpg)
TWO DISTINCT PRODUCT TYPESD il & P k P f t 320 /d
VALU
Daily
Daily & Peak Performance at 320 mg/d UE
PR
O
Supplementation to Improve Learning & Memory Same Day
OP
OS
ITISame Day Supplementation for Improved Mental Performance in Cognitively
ON
Cognitively Demanding Environments
23
![Page 24: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/24.jpg)
CO
GGN
ITIVE
FASTER LEARNING
ENHANCED MEMORY
E H
EA
LT
ENHANCED MEMORY
IMPROVED MENTAL PERFORMANCE
H
A FOUNDATIONAL INGREDIENT FOR COGNITIVE HEALTH
PERFORMANCE
A FOUNDATIONAL INGREDIENT FOR COGNITIVE HEALTH FORMULATIONS SUPPORTING MEMORY, LEARNING AND INTELLECTUAL PERFORMANCE
24
![Page 25: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/25.jpg)
APPENDIX
25
![Page 26: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/26.jpg)
COGNITIVE FUNCTIONING GLOSSARY CLINN
ICA
L R
Learning/Learning rate Acquisition new information or reinforcement of existing knowledge or skills. May involve synthesizing different types of information.
RE
SE
AR
C
synthesizing different types of information.
Working Memory Process that provides temporary storage and manipulation of the information necessary for complex cognitive tasks such as learning C
Hcomplex cognitive tasks such as learning,reasoning and language comprehension.
Memory Consolidation Transition of information from short-term to long-term memory.
Information Retention The second stage of memory after encoding and before retrieval.
Visual Information Processing
A measure of the ability to sustain attention.
26
![Page 27: NOVEMBER 4, 2013 CO G NITIV E FASTER LEARNING HEALT ... SYNAPSA Customer Presentation 1… · (Infotrends 2011) PORT VAST NEED & MARKET OPPORTUNITY U FOR SUPPORT IN AREAS OF COGNITIVE](https://reader034.vdocument.in/reader034/viewer/2022052022/60378471932ad8451c453fe9/html5/thumbnails/27.jpg)
BACOPA MONNIERI ALTERNATIVESF i & th L k f bli h d d/ t di
CO
M
Focus on aging & other. Lack of published and/or new studies.
• Studies focusing on trauma & children
MP
ETITI
BACOPIN™ • Few published studies• No recent studies• Website not updated since 2005• 3 Studies, 2 focusing on elderly & 1 on
VE
AN
A
BACOMIND™3 Studies, 2 focusing on elderly & 1 on children with low IQ
• No ongoing support
BACOGNIZE™ • No clinical studies actually published
ALY
SIS
BACOGNIZE™ No clinical studies actually published • Borrowed science (from Synapsa™)
Generic • No published clinical studiesGeneric p• Lack of transparency on sourcing/quality
27